{"id":"bortezomib-rituximab-dexamethasone","safety":{"commonSideEffects":[{"rate":"40%","effect":"Neutropenia"},{"rate":"30%","effect":"Thrombocytopenia"},{"rate":"20%","effect":"Anemia"},{"rate":"50%","effect":"Fatigue"},{"rate":"30%","effect":"Diarrhea"},{"rate":"20%","effect":"Nausea"},{"rate":"10%","effect":"Vomiting"},{"rate":"20%","effect":"Pyrexia"},{"rate":"10%","effect":"Headache"},{"rate":"5%","effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL1201576","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Bortezomib is a proteasome inhibitor that blocks the action of proteasomes, which are complexes that break down proteins in cells. This leads to an accumulation of defective proteins, which can trigger apoptosis in cancer cells.","oneSentence":"Proteasome inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:33.373Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT05736419","phase":"PHASE2","title":"A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-02-09","conditions":"Sickle Cell Disease, Thalassemia, Beta, Thalassemia","enrollment":24},{"nctId":"NCT03136146","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-08-09","conditions":"Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia","enrollment":42},{"nctId":"NCT02844322","phase":"PHASE4","title":"The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-05","conditions":"Waldenström Macroglobulinemia","enrollment":35},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT04776850","phase":"EARLY_PHASE1","title":"Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-12-29","conditions":"Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia","enrollment":""},{"nctId":"NCT01788020","phase":"PHASE3","title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2013-11","conditions":"Waldenström's Macroglobulinemia","enrollment":202},{"nctId":"NCT03697356","phase":"PHASE2","title":"R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia","status":"RECRUITING","sponsor":"Kosin University Gospel Hospital","startDate":"2019-03-06","conditions":"Waldenström's Macroglobulinemia","enrollment":54},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT01805557","phase":"PHASE2, PHASE3","title":"Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-02-04","conditions":"Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":108},{"nctId":"NCT00477412","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-03","conditions":"Mantle Cell Lymphoma","enrollment":107},{"nctId":"NCT01381692","phase":"PHASE1, PHASE2","title":"Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-07-20","conditions":"Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma","enrollment":9},{"nctId":"NCT01046006","phase":"PHASE2","title":"Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia","status":"COMPLETED","sponsor":"Meletios A. Dimopoulos","startDate":"2007-03","conditions":"Waldenstrom's Macroglobulinemia","enrollment":59},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00581776","phase":"PHASE2","title":"Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2005-05","conditions":"Mantle Cell Lymphoma","enrollment":30},{"nctId":"NCT00711828","phase":"PHASE2","title":"Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2008-08","conditions":"Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma","enrollment":21},{"nctId":"NCT00413959","phase":"PHASE2","title":"VELCADE,Rituximab,Cyclophosphamide and Decadron","status":"TERMINATED","sponsor":"Oncology Specialists, S.C.","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Lymphoma, B-Cell","enrollment":12},{"nctId":"NCT00504751","phase":"PHASE2","title":"Phase II Study of \"VIPER\" Chemotherapy in Rel/Ref DLBCL","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-05","conditions":"Non-Hodgkin's Lymphoma","enrollment":15},{"nctId":"NCT01449344","phase":"PHASE3","title":"Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL","status":"UNKNOWN","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2009-05-09","conditions":"Mantle Cell Lymphoma","enrollment":128},{"nctId":"NCT02971982","phase":"PHASE1, PHASE2","title":"PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2016-10","conditions":"Treatment","enrollment":40},{"nctId":"NCT00250926","phase":"PHASE2","title":"Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2005-10","conditions":"Waldenstrom's Macroglobulinemia","enrollment":23},{"nctId":"NCT00740415","phase":"PHASE2","title":"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2007-06","conditions":"Lymphoma","enrollment":39},{"nctId":"NCT01457144","phase":"PHASE2","title":"Study of Mantle Cell Lymphoma Treatment by RiBVD","status":"COMPLETED","sponsor":"French Innovative Leukemia Organisation","startDate":"2011-10","conditions":"Mantle Cell Lymphoma","enrollment":76},{"nctId":"NCT00723658","phase":"PHASE2","title":"S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia","status":"WITHDRAWN","sponsor":"SWOG Cancer Research Network","startDate":"2008-09","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT00832234","phase":"PHASE2","title":"Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2006-09","conditions":"Waldenstroms Macroglobulinemia","enrollment":59},{"nctId":"NCT00433537","phase":"PHASE2","title":"Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-05","conditions":"Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma","enrollment":77},{"nctId":"NCT00510887","phase":"PHASE2","title":"Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-01","conditions":"Lymphoma, Follicular","enrollment":14},{"nctId":"NCT00261612","phase":"PHASE2","title":"Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2005-01","conditions":"Lymphoma, Mantle-Cell","enrollment":16}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE KIDNEY INJURY"},{"count":1,"reaction":"ANAPHYLACTIC REACTION"},{"count":1,"reaction":"CHRONIC KIDNEY DISEASE"},{"count":1,"reaction":"END STAGE RENAL DISEASE"},{"count":1,"reaction":"HYPERPARATHYROIDISM SECONDARY"},{"count":1,"reaction":"METABOLIC ACIDOSIS"},{"count":1,"reaction":"NEPHROGENIC ANAEMIA"},{"count":1,"reaction":"PROTEINURIA"},{"count":1,"reaction":"RENAL FAILURE"},{"count":1,"reaction":"TUBULOINTERSTITIAL NEPHRITIS"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BDR"],"phase":"phase_2","status":"active","brandName":"Bortezomib, Rituximab, Dexamethasone","genericName":"Bortezomib, Rituximab, Dexamethasone","companyName":"Meletios A. Dimopoulos","companyId":"meletios-a-dimopoulos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Proteasome inhibitor Used for Multiple myeloma, Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}